Published on : Mar 10, 2015
Patheon announced that it has reached a decision to acquire Agere Pharmaceuticals. Patheon is the global leader of the drug development and delivery solutions market, while Agere Pharmaceuticals is a private CDMO, located in Bend, Ore, that has a unique specialty of enhancing the absorption rate of medications.
A contract development marketing organization (CDMO), Agere is known for leading the market with its medications with enhanced delivery. The company takes an innovative approach through fundamental science, solubilization expertise, and solubilization technologies for the same. The Agere facility at Bend will be used as a solubility center of excellence. It will also be an integral part of pharmaceutical development services (PDS) run by Patheon. None of the companies have commented anything about the terms of acquisition.
Patheon intends to combine Agere’s solubility expertise with its large-scale network of scientists spread across the globe, its development and manufacturing capacities, and cater to the customers seeking to better the absorption rate of the medications. These customers will also have help from early development with commercialization.
President, global pharmaceutical development services and executive vice president global sales and marketing, Michael Lehmann stated that the company is looking at offering solutions to customers that are integrated solutions to address the growing drug delivery needs. He further added that the new capacity will allow the company to sell formulations with expertise of solubility enhancement. The acquisition will strengthen Patheon’s position in the market as it will add a new dimension of design automation and scientific acumen.